GlaxoSmithKline to acquire Reliant
- Share via
From Times Wire Reports
GlaxoSmithKline will buy heart drug specialist Reliant Pharmaceuticals Inc. for $1.65 billion in cash, the company said. GSK expects the transaction will add to earnings in 2008 and create additional value in following years.
Privately held Reliant develops specialty medicines combating heart disease and holds U.S. rights to Lovaza, a treatment for adult patients with very high levels of triglycerides.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
